Nine-Week Immunotherapy Keeps Colon Cancer Patients Cancer-Free for Nearly Three Years

In a result that has stunned oncologists, every single patient in a UK-led trial who received just nine weeks of immunotherapy before surgery for colorectal cancer has remained cancer-free nearly three years later. All 32 patients in the NEOPRISM-CRC trial — those with stage two or three disease — have defied the odds that typically see around a quarter of patients relapse within three years under standard care.

The standard approach is brutal: surgery followed by months of chemotherapy. This trial flipped that script, using pembrolizumab — a drug already familiar to oncologists — before the surgeon's knife ever touched tissue. The result suggests that timing, not just the drug itself, may be everything.

What's particularly striking is that this wasn't a new wonder drug. Pembrolizumab is already used in multiple cancer types. The innovation was in when and how it was deployed. For the 44,000 people diagnosed with bowel cancer in the UK each year, and the millions more globally, this could represent a genuine paradigm shift.

Key Facts & Figures - 32 patients in trial, all cancer-free at ~3 years - Standard approach: ~25% relapse within 3 years - Bowel cancer: 4th most common cancer in UK (44,000 cases/year) - 2,000–3,000 patients/year could benefit from this specific approach - Drug: pembrolizumab (existing immunotherapy, not experimental) - Trial: NEOPRISM-CRC, UK-led - Source: ScienceDaily / Fox News Health / Peer-reviewed publication

Context & Background Immunotherapy has transformed cancer treatment over the past decade, but primarily in advanced or metastatic disease. Using it earlier in the treatment pathway — as neoadjuvant therapy — is an emerging strategy, but results this dramatic are extremely rare. The study challenges a decades-old assumption about the sequence of cancer treatment.

Limitations & Caveats - Only 32 patients — small sample size - Specific genetic subtype (likely MSI-high/dMMR), not all colorectal cancers - Three-year follow-up is promising but not definitive - Long-term side effects of immunotherapy still being studied - Cost and NHS capacity for widespread adoption unclear

Sources - Lead researcher at Imperial College London or trial coordinating centre - Colorectal cancer patient advocacy group (Bowel Cancer UK) - NHS oncologist for perspective on implementation challenges

---